Home
overview
After almost ten years of research into the field of angiogenesis late stage clinical trials have been conducted and shown efficacy in treating Cancer. This recent development has created a surge of interest in angiogenesis and promises to widen the field to other therapeutic areas.

SMi’s 3rd Annual Conference Angiogenesis aims to cover:

  • New opportunities for drug development across therapeutic areas
  • The new and promising agents currently in development
  • The challenges with angiogenesis research and current solutions
  • Utilising imaging in angiogenesis and standardisation

    A unique opportunity to learn from leading experts in the field including:
    Dr William Li, President & Medical Director, Angiogenesis Foundation
    Dr J Anthony Ware, Vice President, Cardiovascular Research & Clinical Investigation, Eli Lilly
    Dr Susan Kelley, Vice President, Product Development, Bayer
    Dr David Lebwohl, Executive Director, Phase II/III Clinical Development, Novartis Oncology
    Dr Andreas Voss, Physician, Lung Cancer Disease Area, AstraZeneca
    Dr David Stirling, Chief Scientific Officer & Executive Vice President, Research & Development, Celgene
    Dr Hanspeter Gerber, Scientist, Genentech
    Dr Ralph Kelly, Vice President, Clinical Affairs, Genzyme
    Dr John Rudge, Director, Angiogenesis, Regeneron
    Dr John Reddington, Senior Vice President, Valentis

    BENEFITS OF ATTENDING:
    · KEY DEVELOPMENTS ACROSS DIFFERENT THERAPEUTIC AREAS: Investigate the progress in oncology, cardiology, wound healing and ophthalmology
    · ANGIOGENESIS STIMULATION: Understand the rationale, hear updates on current drugs in the pipeline and discuss directions for future research
    · ANGIOGENESIS INHIBITION: Hear case studies of some of the most exciting novel agents and assess their potential
    · IMAGING: Learn about the latest technologies and how imaging can be integrated into clinical trials

  • Conference programme

    8:30 Registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr William Li

    Dr William Li, President & Medical Director, The Angiogenesis Foundation

    9:10 KEYNOTE ADDRESS: NOVEL APPROACHES TO ANGIOGENESIS CONTROL

    Dr William Li

    Dr William Li, President & Medical Director, The Angiogenesis Foundation

  • Validation of signal transduction pathways
  • Learnings from angiogenesis programmes to date
  • What are the next generation of pro- and anti-angiogenic agents?
  • Multi-targeting and combinatorial strategies for angiogenesis control
  • Select targeting for vulnerable states of vascular development
  • Unmet clinical needs and the future of the angiogenesis market
  • 9:40 FROM DISEASE MODELLING TO DRUG DISCOVERY

    Dr Amy Rubinstein

    Dr Amy Rubinstein, Director of Research, Zygogen

  • Stable transgenic fish lines with tissue-specific expression
  • Combining relevance of in vivo environment as well as potential for HTS
  • Potential for identification of novel targets
  • Integrating zebrafish into preclinical drug discovery
  • Advantages and drawbacks of the zebrafish system
  • 10:20 EARLY DEVELOPMENT OF ANGIOGENESIS COMPOUNDS

    Dr Andreas Voss

    Dr Andreas Voss, Physician, Lung Cancer Disease Area, AstraZeneca

  • Developing model systems for angiogenesis research
  • Evaluation of models
  • Bridging the preclinical / clinical gap
  • Novel approaches: case studies
  • 11:00 Morning Coffee

    11:20 DETECTION OF BREAST ANGIOGENESIS USING OPTICAL SYSTEMS

  • Diagnostic accuracy of current technologies
  • Choice of parameters
  • Image analysis technology: producing higher quality images
  • Producing quantitative information at an earlier stage
  • Contrast agents
  • Assessing the progress of optical systems
  • Philip Thomas

    Philip Thomas, Chief Executive Officer, DOBI Medical International

    Dr Angelo Secci

    Dr Angelo Secci, Vice President, Clinical Research, DOBI Medical International

    12:00 NON-VIRAL GENE THERAPY WITH FIBROBLAST GROWTH FACTORS

    Dr Michael Coleman

    Dr Michael Coleman, Vice President, Research & Development, Gencell

  • Efficacy of NV1FGF in animal models
  • Safety and tolerability of repeated doses
  • Clinical studies in critical limb ischemia
  • Future directions
  • 12:40 Networking Lunch

    14:00 THERAPEUTIC ANGIOGENESIS

    Dr J Anthony Ware

    Dr J Anthony Ware, Vice President, Cardiovascular Research & Clinical Investigation, Eli Lilly

  • Rationale for therapeutic angiogenesis
  • Review of clinical trials
  • Reasons for disappointing results
  • A vignette on thromboxane A2 agonists and angiogenesis
  • Recommendations for further studies
  • 14:40 THERAPEUTIC ANGIOGENESIS TO REVERSE NEUROPATHY

    Dr Douglas Losordo

    Dr Douglas Losordo, Chief, Cardiovascular Research, St Elizabeth’s Medical Center

  • Animal models: what did we learn?
  • Early indications from clinical results to date
  • What is the potential for wound healing?
  • What does the future hold for reversal of neuropathy?
  • Commercial potential
  • 15:20 Afternoon Tea

    15:40 ANGIOGENIC THROMBIN PEPTIDE TP508 (CHRYSALINâ) EFFECTS ON DIABETIC WOUNDS, FRACTURES AND ISCHEMIC MYOCARDIUM

    Dr Darrell Carney

    Dr Darrell Carney, President & Chief Executive Officer, Chrysalis BioTechnology

  • Increasing understanding of the mechanism of thrombin and thrombin peptide-induced angiogenesis
  • Insights into the role of thrombin peptides in angiogenesis signalling pathway
  • Phase II clinical trials for Chrysalin for the treatment of chronic diabetic ulcers
  • Potential use of Chrysalin for other tissue repair indications - Fracture repair - Myocardial ischemia
  • Future of thrombin and thrombin peptides in angiogenesis related tissue repair
  • 16:20 THERAPEUTIC ANGIOGENESIS WITH A HIF-1 ALPHA TRANSGENE

    Dr Ralph Kelly

    Dr Ralph Kelly, Vice President, Clinical Affairs, Genzyme

  • There is evidence that a combination of two or more angiogenic cytokines may be superior to a single cytokine for the induction of therapeutic angiogenesis
  • HIF-1 alpha, a transcription factor that is responsive to cellular oxygen concentration, activates a number of genes that promote a coordinated cellular response to hypoxia
  • A number of pro-angiogenic and pro-arteriogenic pathways are upregulated by HIF-1 alpha, including all VEGF-A isoforms, PlGF, PDGF, and several angiopoietins, among others
  • Preclinical studies have demonstrated efficacy in experimental animal models of coronary artery and peripheral vascular ischemic disease
  • A completed phase I critical limb ischemia trial has documented the safety and provided preliminary evidence of bioactivity, for adenoviral delivery of constitutively active HIF-1 alpha transgene
  • 17:00 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr David Lebwohl

    Dr David Lebwohl, Executive Director, Phase II/III Clinical Development, Novartis Oncology

    9:10 INTEGRATION OF IMAGING INTO ANGIOGENESIS CLINICAL TRIALS

    Dr Sandra Chica

    Dr Sandra Chica, Medical Director, Perceptive Informatics
    View Bio

  • Imaging and study design
  • Integration of imaging studies into the clinical programme
  • Tackling the problem of data reproducibility
  • Standardisation of imaging approaches: crucial for success
  • Regulatory issues: an update on the FDA’s standpoint
  • 9:40 DEL-1 FOR THERAPEUTIC ANGIOGENESIS

    Dr John Reddington

    Dr John Reddington, Senior Vice President, Valentis

  • Unique mechanism of action
  • Preclinical studies -Formulation optimization -Peripheral arterial disease -Ischemic heart disease
  • Phase 1 results for the treatment of intermittent claudication
  • Phase II: Delta-PAD trial design
  • 10:20 NOVEL ONCOLOGY AGENTS TARGETING DIFFERENT ANTI-ANGIOGENIC PATHWAYS

    Dr Udo Klein

    Dr Udo Klein, Vice President, Research & Development, EntreMed

  • Panzem ® (2-methozyestradiol)
  • Analogs of 2-methoxyestradiol
  • PAR-2 antagonists
  • TFPI peptides
  • FGF-2 vaccine
  • 11:00 Morning Coffee

    11:20 ASSESSING THE POTENTIAL OF VEGF RECEPTOR INHIBITION FOR CANCER TREATMENT

    Dr David Lebwohl

    Dr David Lebwohl, Executive Director, Phase II/III Clinical Development, Novartis Oncology

  • Learning more about the VEGF family of growth factors
  • Strategies to target VEGFs in cancer treatment
  • Clinical trial designs
  • Contrast-enhanced MRI as a biomarker for pharmacological response
  • Results update: phase III trials of PTK787/ ZK222584 in colorectal cancer
  • Future predictions for anti-VEGF therapies
  • 12:00 THE SCOPE OF POTENT VEGF BLOCKERS

    Dr John Rudge

    Dr John Rudge, Director, Angiogenesis, Regeneron

  • Preclinical findings
  • An explanation of the Trap technology platform
  • Shrinking of established tumours
  • Results to date
  • Potential for ophthalmology and other indications
  • 12:40 Networking Lunch

    13:40 ANTI-ANGIOGENIC RAF KINASE INHIBITOR

    Dr Susan Kelley

    Dr Susan Kelley, Vice President, Product Development, Bayer

  • Effects of BAY 43-9006 on tumor progression and biologic markers
  • Anti-cancer activity in phase I and phase II clinical trials in renal cell cancer and other tumors
  • Optimizing the potential of anti-angiogenic signal transduction inhibitors
  • Studies of BAY 43-9006 in combination with standard cancer therapies
  • 14:20 SELECTIVE INHIBITION OF VEGFR2 ACTIVITY WITH A MONOCLONAL ANTI-VEGF ANTIBODY

    Dr Rolf Brekken

    Dr Rolf Brekken, Assistant Professor, Division of Surgical Oncology, UT-Southwestern Medical Center/ Peregrine Pharmaceuticals

  • Validation in vitro
  • Animal tumour models
  • Imaging studies
  • Progress on humanization and testing
  • 15:00 MONOCLONAL ANTIBODIES TO INHIBIT TUMOUR ANGIOGENESIS

    Dr Peter Bohlen

    Dr Peter Bohlen, Senior Vice President, Research, ImClone Systems

    15:40 Afternoon Tea

    16:00 A NEW CLASS OF IMMUNOMODULATORY DRUGS (IMIDS)

    Dr David Stirling

    Dr David Stirling, Chief Scientific Officer & Executive Vice President, Pharmaceutical Research & Development, Celgene

  • IMiDs anti-angiogenic mechanism
  • Affecting multiple pathways
  • Treating hematological and solid tumour cancers: response rates
  • Pivotal phase III special protocol assessment trials
  • Results for multiple myeloma
    Results for myelodysplastic syndrome
  • Safety profile
    Where is the research headed from here?
  • 16:40 AVASTIN: WHAT HAVE WE LEARNT AND WHERE ARE WE HEADED?

    Dr Hanspeter Gerber

    Dr Hanspeter Gerber, Scientist, Genentech

  • How effective is Avastin at prolonging patient life?
  • Phase III results for colorectal cancer in combination with standard chemotherapy
  • Additional study results for first-line metastatic colorectal cancer
  • Broad late stage clinical development programme
  • Potential for metastatic breast cancer, renal cell carcinoma and non-small cell lung cancer
  • Potential combination strategies
    Moving onward from this success: how can we improve anti-VEGF antibodies?
  • 17:20 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.